Dr Scott J. Roberts

Porcupine inhibition is a promising pharmacological treatment for severe sclerosteosis pathologies - Bone Research Bone Research - Porcupine inhibition is a promising pharmacological treatment for severe sclerosteosis pathologies

📢 New Publication: I am delighted to share our most recent paper, published in @natureportfolio.nature.com Journal Bone Research "Porcupine inhibition is a promising pharmacological treatment for severe sclerosteosis pathologies".

www.nature.com/articles/s41...

Excited to share the latest chapter of our work on fat-joint interorgan crosstalk in knee OA, featuring the role of complement factor D secreted by fat in knee pain. Link here: bit.ly/42Og5hJ

Thanks to @farsh-g.bsky.social for all of your support - @thehopefulscie1.bsky.social and all coauthors!

CYR61 delivery promotes angiogenesis during bone fracture repair - npj Regenerative Medicine npj Regenerative Medicine - CYR61 delivery promotes angiogenesis during bone fracture repair

Annemarie’s latest paper is out today!

CYR61 delivery promotes angiogenesis during bone fracture repair.

www.nature.com/articles/s41...

@amilangscience.bsky.social @madhura0327.bsky.social @cpane94.bsky.social @eseidlscience.bsky.social @ricgottardi.bsky.social et al.

Porcupine inhibition is a promising pharmacological treatment for severe sclerosteosis pathologies - Bone Research Bone Research - Porcupine inhibition is a promising pharmacological treatment for severe sclerosteosis pathologies

Enzyme Porcupine inhibition of Wnt signaling-a promising treatment forsclerosteosis - rare Dz caused by SOST mutations & loss of functional sclerostin. Results in high bone mass & skeletal overgrowth (Sxs of facial paralysis, hearing loss, incr intracranial pressure www.nature.com/articles/s41...

This study was published in Bone Research, the team investigates the impact of LGK974, a Porcupine inhibitor, on bone mass regulation in a sclerosteosis mouse model.
#Bone #Sclerosteosis
Details: doi.org/10.1038/s414...

Porcupine inhibition represents a promising treatment for sclerosteosis patients New research from the Royal Veterinary College (RVC) has identified porcupine inhibition—a strategy that blocks a key bone-related signaling pathway (Wnt)—as a promising pharmacological treatment for severe sclerosteosis.

Porcupine inhibition, targeting the Wnt signaling pathway, shows promise as a treatment for sclerosteosis, potentially reducing the need for high-risk surgeries in this rare genetic disorder. doi.org/g9fm67

💡A huge shout out to all of the authors of this study Tim Dreyer, Jacob Keen, Leah Wells, Mark Hopkinson, Isabel Orriss, Gill Holdsworth and Andy Pitsillides - you are all great! Also many thanks to our funders UCB Pharma for your continued support.

📋 Importance: LGK974 therapy would likely be an option for treating disease early in children. This would potentially avoid risky surgical treatments such as skull decompression surgery.

💊 What We Found: A drug called LGK974 reduced skull and ear bone mass of young mice with sclerosteosis disease, indicating that it effectively limits skeletal overgrowth at sites with severe/fatal pathology.

🔬 What We Did: We screened distinct drugs in cells, and a mouse model of sclerosteosis. This is a disease characterised by skeletal overgrowth, potentially fatal elevated intracranial pressure, and deafness. Sclerosteosis has no pharmaceutical therapy, and is managed only through high-risk surgery.

Porcupine inhibition is a promising pharmacological treatment for severe sclerosteosis pathologies - Bone Research Bone Research - Porcupine inhibition is a promising pharmacological treatment for severe sclerosteosis pathologies

📢 New Publication: I am delighted to share our most recent paper, published in @natureportfolio.nature.com Journal Bone Research "Porcupine inhibition is a promising pharmacological treatment for severe sclerosteosis pathologies".

www.nature.com/articles/s41...